Equities research analysts expect Nu Skin Enterprises (NYSE:NUS) to report $561.32 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Nu Skin Enterprises’ earnings, with the highest sales estimate coming in at $567.09 million and the lowest estimate coming in at $555.54 million. Nu Skin Enterprises reported sales of $499.10 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.5%. The business is scheduled to issue its next quarterly earnings results after the market closes on Thursday, April 26th.
On average, analysts expect that Nu Skin Enterprises will report full year sales of $2.47 billion for the current year, with estimates ranging from $2.46 billion to $2.47 billion. For the next year, analysts forecast that the firm will report sales of $2.53 billion per share. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Nu Skin Enterprises.
Nu Skin Enterprises (NYSE:NUS) last posted its quarterly earnings data on Thursday, February 15th. The company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.01. The business had revenue of $666.20 million during the quarter, compared to the consensus estimate of $667.39 million. Nu Skin Enterprises had a net margin of 5.68% and a return on equity of 25.23%. The company’s quarterly revenue was up 25.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.79 earnings per share.
A number of equities research analysts have weighed in on NUS shares. Deutsche Bank upped their price target on shares of Nu Skin Enterprises from $75.00 to $77.00 and gave the company a “buy” rating in a report on Friday, February 16th. Pivotal Research reissued a “buy” rating and issued a $90.00 price target on shares of Nu Skin Enterprises in a report on Friday, February 16th. ValuEngine raised shares of Nu Skin Enterprises from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Citigroup reissued a “buy” rating and issued a $81.00 price target (up from $70.00) on shares of Nu Skin Enterprises in a report on Tuesday, January 23rd. Finally, Zacks Investment Research raised shares of Nu Skin Enterprises from a “sell” rating to a “hold” rating and set a $78.00 price target for the company in a report on Saturday, December 30th. Two analysts have rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $71.29.
In other Nu Skin Enterprises news, General Counsel D Matthew Dorny sold 3,000 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $72.69, for a total transaction of $218,070.00. Following the completion of the sale, the general counsel now directly owns 44,399 shares of the company’s stock, valued at $3,227,363.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Pisano R. Thomas sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $72.00, for a total transaction of $1,080,000.00. Following the sale, the director now directly owns 47,437 shares of the company’s stock, valued at $3,415,464. The disclosure for this sale can be found here. Insiders sold a total of 127,865 shares of company stock valued at $9,414,737 over the last three months. 5.20% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Nu Skin Enterprises by 38.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock valued at $210,000 after buying an additional 858 shares in the last quarter. Meeder Asset Management Inc. lifted its stake in Nu Skin Enterprises by 7.9% during the fourth quarter. Meeder Asset Management Inc. now owns 12,830 shares of the company’s stock valued at $875,000 after buying an additional 939 shares in the last quarter. Bank of Montreal Can lifted its stake in Nu Skin Enterprises by 12.0% during the fourth quarter. Bank of Montreal Can now owns 9,680 shares of the company’s stock valued at $660,000 after buying an additional 1,034 shares in the last quarter. KBC Group NV lifted its stake in Nu Skin Enterprises by 28.2% during the fourth quarter. KBC Group NV now owns 6,820 shares of the company’s stock valued at $465,000 after buying an additional 1,500 shares in the last quarter. Finally, Cerebellum GP LLC purchased a new stake in Nu Skin Enterprises during the fourth quarter valued at about $124,000. 76.47% of the stock is owned by institutional investors.
Shares of NYSE NUS opened at $71.04 on Friday. Nu Skin Enterprises has a twelve month low of $52.88 and a twelve month high of $76.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.74 and a quick ratio of 1.17. The stock has a market capitalization of $3,755.80, a price-to-earnings ratio of 21.99, a price-to-earnings-growth ratio of 2.07 and a beta of 1.36.
TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/20/brokerages-anticipate-nu-skin-enterprises-nus-will-post-quarterly-sales-of-561-32-million.html.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.